score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline		Guideline	Somatic Variant	KIT	Missense	p.W557C	0.1059	255.0	0.0	0.0		Putatively Actionable	Imatinib	KIT inhibition	Targeted therapy	KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.	National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.W557C (Missense)	0	TGCT_CONSENSUS3	TCGA-2G-AAHT-01A-11D-A42Y-10	TCGA-2G-AAHT-10A-01D-A433-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.1837	196.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	TGCT_CONSENSUS3	TCGA-XE-AAO6-01A-31D-A435-10	TCGA-XE-AAO6-10A-01D-A438-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.1771	96.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	TGCT_CONSENSUS3	TCGA-XY-A89B-01A-11D-A435-10	TCGA-XY-A89B-10A-01D-A438-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12D	0.1714	210.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12D (Missense)	1	TGCT_CONSENSUS3	TCGA-SB-A76C-01A-11D-A435-10	TCGA-SB-A76C-10A-01D-A438-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12S	0.1547	181.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12S (Missense)	1	TGCT_CONSENSUS3	TCGA-YU-A90Q-01A-11D-A435-10	TCGA-YU-A90Q-10A-01D-A438-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1101	436.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	TGCT_CONSENSUS3	TCGA-2G-AAEX-01A-11D-A42Y-10	TCGA-2G-AAEX-10A-01D-A433-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2475	299.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	TGCT_CONSENSUS3	TCGA-XE-A8H5-01A-11D-A435-10	TCGA-XE-A8H5-10A-01D-A438-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P1178L	0.225	160.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P1178L (Missense)	1	TGCT_CONSENSUS3	TCGA-XE-AANI-01A-11D-A435-10	TCGA-XE-AANI-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.Y578C	0.2791	86.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.Y578C (Missense)		TGCT_CONSENSUS3	TCGA-XE-AANV-01A-11D-A435-10	TCGA-XE-AANV-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D816H	0.234	94.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D816H (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAHA-01A-11D-A42Y-10	TCGA-2G-AAHA-10A-01D-A433-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D816H	0.7037	54.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D816H (Missense)		TGCT_CONSENSUS3	TCGA-4K-AA1G-01A-11D-A435-10	TCGA-4K-AA1G-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D816H	0.4407	59.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D816H (Missense)		TGCT_CONSENSUS3	TCGA-XE-AAOF-01A-11D-A435-10	TCGA-XE-AAOF-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D816H	0.3462	78.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D816H (Missense)		TGCT_CONSENSUS3	TCGA-YU-A90Q-01A-11D-A435-10	TCGA-YU-A90Q-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D816Y	0.3933	89.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D816Y (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAFE-01A-11D-A42Y-10	TCGA-2G-AAFE-10A-01D-A433-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D816Y	0.25	44.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D816Y (Missense)		TGCT_CONSENSUS3	TCGA-2X-A9D6-01A-11D-A435-10	TCGA-2X-A9D6-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D816V	0.6071	56.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D816V (Missense)		TGCT_CONSENSUS3	TCGA-XE-AANR-01A-11D-A435-10	TCGA-XE-AANR-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822Y	0.225	80.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822Y (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAHN-01A-11D-A42Y-10	TCGA-2G-AAHN-10A-01D-A433-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822K	0.4937	79.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822K (Missense)		TGCT_CONSENSUS3	TCGA-YU-A912-01A-11D-A435-10	TCGA-YU-A912-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822K	0.7769	130.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822K (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAHL-01A-11D-A42Y-10	TCGA-2G-AAHL-10A-01D-A433-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N822K	0.407	86.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N822K (Missense)		TGCT_CONSENSUS3	TCGA-2X-A9D5-01A-11D-A435-10	TCGA-2X-A9D5-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.V825D	0.36	50.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V825D (Missense)		TGCT_CONSENSUS3	TCGA-XE-AANV-01A-11D-A435-10	TCGA-XE-AANV-10A-01D-A438-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.A829P	0.3067	75.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.A829P (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAH3-01A-11D-A42Y-10	TCGA-2G-AAH3-10A-01D-A433-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.A829P	0.2394	71.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.A829P (Missense)		TGCT_CONSENSUS3	TCGA-ZM-AA0H-01A-11D-A435-10	TCGA-ZM-AA0H-10A-01D-A438-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A146V	0.1809	94.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A146V (Missense)	1	TGCT_CONSENSUS3	TCGA-XY-A9T9-01A-11D-A435-10	TCGA-XY-A9T9-10A-01D-A438-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.E63K	0.1934	212.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.E63K (Missense)	1	TGCT_CONSENSUS3	TCGA-2G-AAG9-01A-11D-A42Y-10	TCGA-2G-AAG9-10A-01D-A433-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61L	0.1429	126.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61L (Missense)	1	TGCT_CONSENSUS3	TCGA-2G-AAF4-01A-11D-A42Y-10	TCGA-2G-AAF4-10A-01D-A433-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61L	0.1163	215.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61L (Missense)	1	TGCT_CONSENSUS3	TCGA-2G-AAH8-01A-11D-A42Y-10	TCGA-2G-AAH8-10A-01D-A433-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61R	0.2961	179.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61R (Missense)	1	TGCT_CONSENSUS3	TCGA-S6-A8JW-01A-11D-A435-10	TCGA-S6-A8JW-10A-01D-A438-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.2283	219.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	TGCT_CONSENSUS3	TCGA-2G-AAEW-01A-11D-A42Y-10	TCGA-2G-AAEW-10A-01D-A433-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.1767	232.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	TGCT_CONSENSUS3	TCGA-2G-AAF6-01A-11D-A42Y-10	TCGA-2G-AAF6-10A-01D-A433-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12A	0.1723	267.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12A (Missense)	1	TGCT_CONSENSUS3	TCGA-2G-AAHA-01A-11D-A42Y-10	TCGA-2G-AAHA-10A-01D-A433-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12R	0.3735	324.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12R (Missense)	1	TGCT_CONSENSUS3	TCGA-VF-A8AC-01A-11D-A435-10	TCGA-VF-A8AC-10A-01D-A438-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.1186	177.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	TGCT_CONSENSUS3	TCGA-4K-AA1H-01A-11D-A435-10	TCGA-4K-AA1H-10A-01D-A438-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.1616	99.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	TGCT_CONSENSUS3	TCGA-XE-AAOF-01A-11D-A435-10	TCGA-XE-AAOF-10A-01D-A438-10
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.K373N	0.2066	121.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.K373N (Missense)		TGCT_CONSENSUS3	TCGA-XE-AANV-01A-11D-A435-10	TCGA-XE-AANV-10A-01D-A438-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L667F	0.1975	81.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L667F (Missense)		TGCT_CONSENSUS3	TCGA-XY-A89B-01A-11D-A435-10	TCGA-XY-A89B-10A-01D-A438-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.2955	88.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	TGCT_CONSENSUS3	TCGA-XE-A9SE-01A-21D-A435-10	TCGA-XE-A9SE-10A-01D-A438-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q537*	0.5347	101.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q537* (Nonsense)		TGCT_CONSENSUS3	TCGA-YU-A94I-01A-11D-A435-10	TCGA-YU-A94I-10A-01D-A438-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I882V	0.3023	86.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I882V (Missense)	1	TGCT_CONSENSUS3	TCGA-YU-A90Y-01A-11D-A435-10	TCGA-YU-A90Y-10A-01D-A438-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.G740V	0.2192	146.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.G740V (Missense)		TGCT_CONSENSUS3	TCGA-SB-A6J6-01A-11D-A435-10	TCGA-SB-A6J6-10A-01D-A438-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.D576A	0.3491	212.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.D576A (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAGI-01A-11D-A42Y-10	TCGA-2G-AAGI-10A-01D-A433-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.D1067V	0.2601	173.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.D1067V (Missense)	0	TGCT_CONSENSUS3	TCGA-2G-AAH8-01A-11D-A42Y-10	TCGA-2G-AAH8-10A-01D-A433-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D321Y	0.3091	55.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D321Y (Missense)		TGCT_CONSENSUS3	TCGA-2G-AALR-01A-21D-A42Y-10	TCGA-2G-AALR-10A-01D-A433-10
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.R109Q	0.1915	47.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.R109Q (Missense)		TGCT_CONSENSUS3	TCGA-2G-AALF-01A-11D-A42Y-10	TCGA-2G-AALF-10A-01D-A433-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.S340C	0.2667	75.0	0.0	0.0																									NF1 p.S340C (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAGE-01A-21D-A42Y-10	TCGA-2G-AAGE-10A-01D-A433-10
Biologically Relevant				Somatic Variant	RAF1	Missense	p.P308L	0.2593	135.0	0.0	0.0																									RAF1 p.P308L (Missense)		TGCT_CONSENSUS3	TCGA-2G-AAGF-01A-31D-A42Y-10	TCGA-2G-AAGF-10A-01D-A433-10
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	1.0																													COSMIC Signature (version 2) 1 (100%)		TGCT_CONSENSUS3		
